Japan's UMN surges on US approval of Flublok
This article was originally published in Scrip
Shares in the recently listed Japanese venture UMN Pharma went limit-up in Tokyo on 17 January following the US approval the previous day of UMN's technology licensor Protein Sciences' recombinant flu vaccine Flublok (scripintelligence.com, 17 January 2013).
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Japanese major builds presence in novel device technology beyond its conventional therapeutics as looks towards a more holistic future of care.